Page last updated: 2024-10-24

candesartan and Allodynia

candesartan has been researched along with Allodynia in 1 studies

candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.

Research Excerpts

ExcerptRelevanceReference
"Treatment with candesartan and C21 was started on day 1, before VCR treatment, and continued until day 7."1.48Neuroprotective effect of angiotensin II type 2 receptor stimulation in vincristine-induced mechanical allodynia. ( Bessaguet, F; Bouchenaki, H; Danigo, A; Demiot, C; Desmoulière, A; Duchesne, M; Magy, L; Richard, L; Sturtz, F, 2018)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bessaguet, F1
Danigo, A1
Bouchenaki, H1
Duchesne, M1
Magy, L1
Richard, L1
Sturtz, F1
Desmoulière, A1
Demiot, C1

Other Studies

1 other study available for candesartan and Allodynia

ArticleYear
Neuroprotective effect of angiotensin II type 2 receptor stimulation in vincristine-induced mechanical allodynia.
    Pain, 2018, Volume: 159, Issue:12

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Antineopl

2018